Circumvent Pharma

precision medicines, palmitoylome modulation, neurodegeneration

modulatingsmall molecule

circumventpharmaceuticals.com·Portland, Oregon, United States·

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-VWJZ

Projects

N-tert-(Butyl)hydroxylamine (NtBuHA) for Infantile Neuronal Ceroid Lipofuscinosis / CLN1 Batten Disease

preclinical

drug program · high · Thu Nov 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop NtBuHA as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis, also referred to in the supplied company context as CLN1 Batten Disease.

Therapeutic development program supported by an NIH SBIR Phase I grant; intervention is N-tert-(Butyl)hydroxylamine.

NIH SBIR Phase I project 1R43NS100233-01 ran from 2017-03-01 to 2017-11-30 with total cost of $198,790.

Batten Disease precision-medicine program

exploratory

research program · medium

Develop precision medicines for neurodegenerative disease beginning with Batten Disease, using disease biology insights to address rare and potentially broader neurological disorders.

Research and drug-discovery program focused on diseases with predictive animal models and clear clinical development paths; work has generated insights into brain-cell dysfunction, palmitoylation, the palmitoylome, and synaptic biology.

Company site states Circumvent's Batten Disease work produced insights into brain-cell dysfunction, palmitoylation, the palmitoylome, and synaptic biology that it is applying across related neurological diseases.

Reported insights into brain-cell dysfunction, palmitoylation, the palmitoylome, and synaptic biology; no clinical results supplied.

Palmitoylome modulation program for rare neurological disorders

exploratory

platform · medium

Apply Circumvent's Batten Disease-derived insights into palmitoylation, the palmitoylome, and synaptic biology across related rare neurological disorders.

Palmitoylome-focused neurodegeneration research platform intended to inform precision-medicine discovery in rare neurological disease areas.

Company site analysis identifies palmitoylome modulation and application across related neurological diseases, with pipeline areas listed as Batten Disease, CLN1 Batten Disease, and other rare neurological disorders.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Projects

N-tert-(Butyl)hydroxylamine (NtBuHA) for Infantile Neuronal Ceroid Lipofuscinosis / CLN1 Batten Disease

preclinical

drug program · high · Thu Nov 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop NtBuHA as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis, also referred to in the supplied company context as CLN1 Batten Disease.

Therapeutic development program supported by an NIH SBIR Phase I grant; intervention is N-tert-(Butyl)hydroxylamine.

NIH SBIR Phase I project 1R43NS100233-01 ran from 2017-03-01 to 2017-11-30 with total cost of $198,790.

Batten Disease precision-medicine program

exploratory

research program · medium

Develop precision medicines for neurodegenerative disease beginning with Batten Disease, using disease biology insights to address rare and potentially broader neurological disorders.

Reported insights into brain-cell dysfunction, palmitoylation, the palmitoylome, and synaptic biology; no clinical results supplied.

Palmitoylome modulation program for rare neurological disorders

exploratory

platform · medium

Apply Circumvent's Batten Disease-derived insights into palmitoylation, the palmitoylome, and synaptic biology across related rare neurological disorders.

Palmitoylome-focused neurodegeneration research platform intended to inform precision-medicine discovery in rare neurological disease areas.